HRP20161009T1 - Modificirani omci kao inhibitor komplementa - Google Patents
Modificirani omci kao inhibitor komplementa Download PDFInfo
- Publication number
- HRP20161009T1 HRP20161009T1 HRP20161009TT HRP20161009T HRP20161009T1 HR P20161009 T1 HRP20161009 T1 HR P20161009T1 HR P20161009T T HRP20161009T T HR P20161009TT HR P20161009 T HRP20161009 T HR P20161009T HR P20161009 T1 HRP20161009 T1 HR P20161009T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid sequence
- binding activity
- seq
- omci
- Prior art date
Links
- 229940124073 Complement inhibitor Drugs 0.000 title 1
- 239000004074 complement inhibitor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102220572519 Tubulin polyglutamylase complex subunit 1_F36W_mutation Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Claims (9)
1. OmCI polipeptid koji ima smanjenu ili mu nedostaje aktivnost LTB4 vezivanja naznačen time da navedeni OmCI polipeptid sadrži:
(a) sekvencu amino kiseline od SEQ ID NO: 3 koja je modificirana tako da se ukloni ili smanji aktivnost LTB4 vezivanja;
(b) varijantu sekvence amino kiseline koja ima barem 60% identičnosti sa sekvencom amino kiseline od SEQ ID NO: 3 i koja je modificirana tako da se ukloni ili smanji aktivnost LTB4 vezivanja;
(c) varijantu sekvence amino kiseline od SEQ ID NO: 2 koja ima barem 60% identičnosti sa sekvencom amino kiseline između ostataka amino kiseline 19 do 168 iz SEQ ID NO: 2 i koja je modificirana tako da se ukloni ili smanji aktivnost LTB4 vezivanja; ili
(d) fragment sekvence amino kiseline iz (a), (b) ili (c) kojem nedostaje aktivnost LTB4 vezivanja.
2. Polipeptid prema zahtjevu 1 naznačen time da je mutiran jedan ili više ostataka amino kiseline unutar opsega vezivanja navedenog OmCI polipeptida.
3. Polipeptid prema zahtjevu 2 naznačen time da se jedan ili više ostataka amino kiseline koje treba mutirati bira od Phe36, Arg54, Leu57, Gly59, Val72, Met74, Phe76, Trp87, Phe89, Gln105, Arg107, His119, Asp121 i Trp133, pri čemu je numeracija amino kiselina u skladu sa SEQ ID NO: 2.
4. Polipeptid prema zahtjevu 2 ili 3 naznačen time da je barem jedna mutacija amino kiseline odabrana od Phe36Trp i Gly59Trp.
5. Polipeptid prema bilo kojem od prethodnih zahtjeva naznačen time da mu nedostaje aktivnost LTB4 vezivanja.
6. Polinukleotid naznačen time da kodira OmCI polipeptid prema bilo kojem od prethodnih zahtjeva.
7. Vektor naznačen time da sadrži polinukleotid prema zahtjevu 6.
8. Stanica domaćin naznačena time da sadrži polinukleotid prema zahtjevu 6 ili vektor prema zahtjevu 7.
9. Farmaceutski pripravak naznačen time da sadrži:
(a) OmCI polipeptid prema bilo kojem od zahtjeva 1 do 5;
(b) polinukleotid prema zahtjevu 6; ili
(c) vektor prema zahtjevu 7;
i farmaceutski prihvatljiv nosač.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/000311 WO2009098454A2 (en) | 2008-02-05 | 2009-02-05 | Treatment of diseases and conditions mediated by eicosanoids |
| GBGB0906779.4A GB0906779D0 (en) | 2009-04-20 | 2009-04-20 | Composition |
| PCT/GB2010/000213 WO2010100396A1 (en) | 2009-02-05 | 2010-02-04 | Modified omci as a complement inhibitor |
| EP10703194.0A EP2393831B1 (en) | 2009-02-05 | 2010-02-04 | Modified omci as a complement inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161009T1 true HRP20161009T1 (hr) | 2016-10-21 |
Family
ID=40774677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161009TT HRP20161009T1 (hr) | 2009-02-05 | 2016-08-11 | Modificirani omci kao inhibitor komplementa |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120115773A1 (hr) |
| EP (1) | EP2393831B1 (hr) |
| JP (1) | JP2012516694A (hr) |
| CN (1) | CN102341407A (hr) |
| DK (1) | DK2393831T3 (hr) |
| ES (1) | ES2589630T3 (hr) |
| GB (1) | GB0906779D0 (hr) |
| HR (1) | HRP20161009T1 (hr) |
| HU (1) | HUE030084T2 (hr) |
| PL (1) | PL2393831T3 (hr) |
| PT (1) | PT2393831T (hr) |
| SI (1) | SI2393831T1 (hr) |
| WO (1) | WO2010100396A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010505946A (ja) | 2006-10-10 | 2010-02-25 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | 神経再生改善のための補体阻害 |
| JP6618682B2 (ja) | 2011-06-22 | 2019-12-11 | アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 補体阻害剤による慢性障害の治療方法 |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| IL269895B2 (en) * | 2017-04-21 | 2024-06-01 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of autoimmune blistering diseases |
| GB201706406D0 (en) * | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP7153669B2 (ja) * | 2017-04-21 | 2022-10-14 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 瘢痕性眼炎症障害の治療のためのコバーシン |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884188B2 (en) | 2003-06-02 | 2011-02-08 | Varleigh Immuno Pharmaceuticals (Vip) Ltd | Complement inhibitors |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
-
2009
- 2009-04-20 GB GBGB0906779.4A patent/GB0906779D0/en not_active Ceased
-
2010
- 2010-02-04 HU HUE10703194A patent/HUE030084T2/en unknown
- 2010-02-04 ES ES10703194.0T patent/ES2589630T3/es active Active
- 2010-02-04 JP JP2011548772A patent/JP2012516694A/ja not_active Withdrawn
- 2010-02-04 PL PL10703194T patent/PL2393831T3/pl unknown
- 2010-02-04 DK DK10703194.0T patent/DK2393831T3/en active
- 2010-02-04 CN CN201080010762XA patent/CN102341407A/zh active Pending
- 2010-02-04 EP EP10703194.0A patent/EP2393831B1/en active Active
- 2010-02-04 SI SI201031250A patent/SI2393831T1/sl unknown
- 2010-02-04 WO PCT/GB2010/000213 patent/WO2010100396A1/en active Application Filing
- 2010-02-04 PT PT107031940T patent/PT2393831T/pt unknown
- 2010-02-04 US US13/148,045 patent/US20120115773A1/en not_active Abandoned
-
2016
- 2016-08-11 HR HRP20161009TT patent/HRP20161009T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010100396A1 (en) | 2010-09-10 |
| HUE030084T2 (en) | 2017-04-28 |
| PL2393831T3 (pl) | 2017-07-31 |
| US20120115773A1 (en) | 2012-05-10 |
| DK2393831T3 (en) | 2016-08-15 |
| CN102341407A (zh) | 2012-02-01 |
| GB0906779D0 (en) | 2009-06-03 |
| PT2393831T (pt) | 2016-08-26 |
| EP2393831A1 (en) | 2011-12-14 |
| EP2393831B1 (en) | 2016-05-18 |
| SI2393831T1 (sl) | 2016-10-28 |
| JP2012516694A (ja) | 2012-07-26 |
| ES2589630T3 (es) | 2016-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161009T1 (hr) | Modificirani omci kao inhibitor komplementa | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| WO2012089833A3 (en) | Expression systems | |
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| MX2012015142A (es) | Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo. | |
| NZ600690A (en) | Fkbp-l and uses thereof | |
| BR112012033404A2 (pt) | polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos. | |
| WO2014118360A3 (en) | Carbohydrate degrading polypeptide and uses thereof | |
| MX2011011215A (es) | Polipeptido que degrada carbohidratos y usos del mismo. | |
| ES2565060T3 (es) | Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos | |
| NZ598351A (en) | Il-17 binding compounds and medical uses thereof | |
| BR112012033703A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
| NZ609216A (en) | Anticancer fusion protein | |
| CO6430475A2 (es) | Polipéptidos que tienen actividad de celulasa | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| WO2014202622A3 (en) | Rasamsonia gene and use thereof | |
| EA201001881A1 (ru) | Пролинспецифичная протеаза из penicillium chrysogenum | |
| WO2013098205A3 (en) | Detergent compositions with lipase variants | |
| JP2015533791A5 (hr) | ||
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| BR112012033714A2 (pt) | polipeptídeo com atividade de acetil xilano esterase e seus usos. | |
| IN2015DN03206A (hr) | ||
| AR075932A1 (es) | Proteasa coagulante de leche de tipo mejorado derivada del microorganismo rhizomucor sp | |
| JP2014529399A5 (hr) |